ArticleRomanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
Dynamic TyG-inflammation-endothelial trajectories and placental histopathology synergistically define a maternal-fetal vascular risk phenotype.
Article in Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Independent Predictors of Major Adverse Cardiac and Hepatic Outcomes Following Acute Liver Complications of Pregnancy; A Retrospective Cohort Study.Archives of academic emergency medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMaternal dysmetabolism and low-grade inflammation accelerate fetal aortic wall thickening. Whether concomitant placental vascular or inflammatory lesions amplify this risk is unknown. Participants, Materials and Methods: 88 women with singleton, anatomically normal pregnancies were phenotyped at 24-26 weeks (visit 1, V1) and 32-34 weeks (visit 2, V2). Dynamic maternal markers [(Δ triglyceride-glucose (TyG) index, Δ interleukin-6 (IL-6), Δ high-sensitivity C-reactive protein (hsCRP), Δ flow-mediated dilation (FMD)] again generated three metabolic inflammatory response phenotypes (MIRP-1∕-2∕-3). Placentas were examined by pathologists. A placental malperfusion-inflammation composite (PMIC) score (0-10) summed semiquantitative grades of maternal vascular malperfusion (MVM), distal villous immaturity, chronic villitis of unknown etiology (CVUE) and acute chorioamnionitis.
resultsAdequate placental tissue was obtained from 84 (95%) dyads. Median PMIC rose step wise from MIRP-1 = 2 [interquartile range (IQR) 1-3] to MIRP-2 = 5 [IQR 3-6] and MIRP-3 = 7 [IQR 6-9] (p<0.001). In mixed effects modelling, PMIC independently predicted fetal abdominal aorta intima-media thickness (IMT) progression [β=+0.012 mm per PMIC point; 95% confidence interval (CI): 0.007-0.017; p<0.001] alongside Δ TyG and Δ IL-6 (R² conditional = 0.61). Mothers in the high risk combined phenotype (MIRP-3 + PMIC ≥7; n=25) exhibited a mean IMT increment of +0.21±0.05 mm vs. +0.06±0.03 mm in the double low reference group (MIRP-1 + PMIC ≤3; n=22; p<0.001). A five variable XGBoost model [Δ TyG, Δ IL-6, Δ FMD, PMIC, baseline body mass index (BMI)] identified fetuses with late gestation high IMT (≥90th percentile) with area under the receiver operating characteristic (AUROC) 0.91, outperforming the parent model lacking PMIC (AUROC 0.88).
conclusionsPlacental vascular and inflammatory lesions potentiate the impact of adverse maternal metabolic inflammatory trajectories on fetal arterial remodeling. Integrating rapid placental histology with dynamic TyG inflammation endothelial indices could refine perinatal risk stratification and guide both ante and postpartum surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.